Latin America Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, Chile, Venezuela), And Segment Forecasts, 2014 - 2025

The Latin American pharmaceutical contract manufacturing services market is anticipated to reach USD 21.0 billion by 2025, according to a new report by Grand View Research, Inc. Low drug registration cost in Latin American countries and continuous economic growth are the key factors contributing to progress in this region. Moreover, Latin America offers higher recruitment rates and relatively high competitive prices in comparison to United States and other European countries.

A forementioned fact pronounces the trend of shifting Contract Manufacturing/Research Organizations (CMO/CRO)’s attention to Latin American countries such as Brazil, Mexico, Argentina, and Colombia. Ongoing adjustment in Latin America to reduce the commodity prices and domestic political turbulence in each country is expected to shape region’s economic growth there by driving revenue generation in the outsourcing market for pharmaceutical development.

Further Key Findings from the study suggest:

Contract manufacturing services accounted for the largest share owing to wide range of services offered by the CMO’s located herein for therapeutic drug development

API/Bulk drug development services accounted for the largest share over the other segments as companies continue to invest for API production capacity enhancement

Rising inclination of drug manufacturers to focus on core competencies such as R&D are observed to have a major impact on the yearly growth of contract research organizations

Brazil held the largest share with respect to revenue generation in 2015

Government’s current initiative to ensure GMP compliance among small and medium-sized pharma companies has contributed for the large share of Brazil

Chile is expected to witness the fastest growth over the forecast period.

Presence of companies offering bioanalytical, biomarker discovery, assay development, and cGMP analytical services can be attributed for the estimated growth

Key players contributing in this market are Lonza; Charles River Laboratories S.A; Jubilant Life Sciences Limited; Boehringer Ingelheim GmbH; Pfizer, Inc. (Pfizer CenterOne); Albany Molecular Research, Inc; QuintilesIMS; and Pharmaceutical Product Development, LLC.

These entities are involved in collaborations with therapeutic research organizations in order to enhance their industrial presence

Table of Contents

Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis
Chapter 2 Executive Summary
Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Drug shortage leading to drive demand for pharmaceutical development
3.1.1.2 Commercial success of biologics for clinical use
3.1.1.3 Lower drug registeration costs and improving economic condition of Latin America
3.1.2 Market restraint analysis
3.1.2.1 Limited outsourcing among big pharma companies’ clients
3.1.2.2 Regulatory issues pertaining to the drug approval
3.2 Penetration & Growth Prospect Mapping, 2015
3.3 Latin America Pharmaceutical Contract Manufacturing Services- SWOT Analysis, By Factor (political & legal, economic and technological)
3.4 Industry Analysis - Porter’s
Chapter 4 Latin America Pharmaceutical Contract Manufacturing Service Market: Services Estimates & Trend Analysis
4.1 Latin America Pharmaceutical Contract Manufacturing Services Market: Service Movement Analysis
4.2 Manufacturing
4.2.1 Latin America manufacturing services market, 2014 - 2025 (USD Million)
4.2.2 API/bulk drugs
4.2.2.1 Latin America API/bulk drugs market, 2014 - 2025 (USD Million)
4.2.3 Advanced drug delivery formulations
4.2.3.1 Latin America advanced drug delivery formulations market, 2014 - 2025 (USD Million)
4.2.4 Packaging
4.2.4.1 Latin America packaging market, 2014 - 2025 (USD Million)
4.2.5 Finished dose formulations
4.2.5.1 Latin America finished dose formulations market, 2014 - 2025 (USD Million)
4.2.5.2 Solid finished dose formulations
4.2.5.2.1 Latin America solid finished dose formulations market, 2014 - 2025 (USD Million)
4.2.5.3 Liquid formulations
4.2.5.3.1 Latin America liquid formulations market, 2014 - 2025 (USD Million)
4.2.5.4 Semi-solid formulations
4.2.5.4.1 Latin America semi-solid formulations market, 2014 - 2025 (USD Million)
4.3 Research
4.3.1 Latin America research services market, 2014 - 2025 (USD Million)
4.3.2 Oncology
4.3.2.1 Latin America oncology market, 2014 - 2025 (USD Million)
4.3.3 Vaccines
4.3.3.1 Latin America vaccines market, 2014 - 2025 (USD Million)
4.3.4 Inflammation & immunology
4.3.4.1 Latin America inflammation & immunology market, 2014 - 2025 (USD Million)
4.3.5 Cardiology
4.3.5.1 Latin America cardiology market, 2014 - 2025 (USD Million)
4.3.6 Neuroscience
4.3.6.1 Latin America neuroscience market, 2014 - 2025 (USD Million)
4.3.7 Other
4.3.7.1 Latin America other research services market, 2014 - 2025 (USD Million)
Chapter 5 Latin America Pharmaceutical Contract Manufacturing Service Market: Country Estimates & Trend Analysis
5.1 Latin America Pharmaceutical Contract Manufacturing Services Market Share By Country, 2015& 2025
5.2 Latin America Pharmaceutical Contract Manufacturing Services Market, 2014 - 2025 (USD Million)
5.3 Brazil
5.3.1 Brazil pharmaceutical contract manufacturing market, 2014 - 2025 (USD Million)
5.4 Mexico
5.4.1 Mexico pharmaceutical contract manufacturing services market, 2014 - 2025 (USD Million)
5.4.2 Colombia
5.4.2.1 Colombia pharmaceutical contract manufacturing services market, 2014 - 2025 (USD Million)
5.4.3 Argentina
5.4.3.1 Argentina pharmaceutical contract manufacturing services market, 2014 - 2025 (USD Million)
5.4.4 Chile
5.4.4.1 Chile pharmaceutical contract manufacturing services market, 2014 - 2025 (USD Million)
5.4.5 Venezuela
5.4.5.1 Venezuela pharmaceutical contract manufacturing services market, 2014 - 2025 (USD Million)
5.4.6 Rest of Latin America
5.4.6.1 Rest of Latin America pharmaceutical contract manufacturing services market, 2014 - 2025 (USD Million)
Chapter 6 Competitive Landscape
6.1 Strategy Framework
6.2 Market Participation Categorization
6.3 Company Profiles
6.3.1 Boehringer Ingelheim GmbH
6.3.1.1 Company overview
6.3.1.2 Financial performance
6.3.1.3 Product benchmarking
6.3.1.4 Strategic initiatives
6.3.2 Lonza
6.3.2.1 Company overview
6.3.2.2 Financial performance
6.3.2.3 Product benchmarking
6.3.2.4 Strategic initiatives
6.3.3 Grifols S.A
6.3.3.1 Company overview
6.3.3.2 Financial performance
6.3.3.3 Product benchmarking
6.3.3.4 Strategic initiatives
6.3.4 Jubilant Life Sciences Limited
6.3.4.1 Company overview
6.3.4.2 Financial Performance
6.3.4.3 Product benchmarking
6.3.4.4 Strategic initiatives
6.3.5 Pfizer, Inc. (Pfizer CenterOne)
6.3.5.1 Company overview
6.3.5.2 Financial performance
6.3.5.3 Product benchmarking
6.3.5.4 Strategic initiatives
6.3.6 Charles River Laboratories International, Inc.
6.3.6.1 Company overview
6.3.6.2 Financial performance
6.3.6.3 Product benchmarking
6.3.6.4 Strategic initiatives
6.3.7 Albany Molecular Research, Inc.
6.3.7.1 Company overview
6.3.7.2 Financial performance
6.3.7.3 Product benchmarking
6.3.7.4 Strategic initiatives
6.3.8 Covance, Inc. (LabCorp)
6.3.8.1 Company overview
6.3.8.2 Financial performance
6.3.8.3 Product benchmarking
6.3.8.4 Strategic initiatives
6.3.9 QuintilesIMS
6.3.9.1 Company overview
6.3.9.2 Financial performance
6.3.9.3 Product benchmarking
6.3.9.4 Strategic initiatives
6.3.10 Baxter BioPharma Solutions
6.3.10.1 Company overview
6.3.10.2 Financial performance
6.3.10.3 Product benchmarking
6.3.10.4 Strategic initiatives
6.3.11 Aenova Holding GmbH
6.3.11.1 Company Overview
6.3.11.2 Financial performance
6.3.11.3 Product benchmarking
6.3.11.4 Strategic initiatives
6.3.12 Vetter Pharma
6.3.12.1 Company Overview
6.3.12.2 Financial performance
6.3.12.3 Product benchmarking
6.3.12.4 Strategic initiatives
6.3.13 Valeant Pharmaceuticals International Inc.
6.3.13.1 Company Overview
6.3.13.2 Financial performance
6.3.13.3 Product benchmarking
6.3.14 Ligand Pharmaceuticals, Inc.
6.3.14.1 Company Overview
6.3.14.2 Financial performance
6.3.14.3 Product benchmarking
6.3.14.4 Strategic initiatives
6.3.15 Pharmaceutical Product Development, LLC
6.3.15.1 Company Overview
6.3.15.2 Financial performance
6.3.15.3 Product benchmarking
6.3.15.4 Strategic initiatives
6.3.16 Recipharm AB.
6.3.16.1 Company Overview
6.3.16.2 Financial performance
6.3.16.3 Product benchmarking
6.3.16.4 Strategic initiatives
6.3.17 AbbVie, Inc.
6.3.17.1 Company Overview
6.3.17.2 Financial performance
6.3.17.3 Product benchmarking
6.3.17.4 Strategic initiatives
6.3.18 Famar Health Care Services
6.3.18.1 Company Overview
6.3.18.2 Financial performance
6.3.18.3 Product benchmarking
6.3.18.4 Strategic initiatives
6.3.19 Catalent Pharma Solutions
6.3.19.1 Company Overview
6.3.19.2 Financial performance
6.3.19.3 Product benchmarking
6.3.19.4 Strategic initiatives
6.3.20 West Pharmaceutical Services, Inc.
6.3.20.1 Company Overview
6.3.20.2 Financial performance
6.3.20.3 Product benchmarking
6.3.20.4 Strategic initiatives